- Home
- BVN vs LEGN Comparison
BVN vs LEGN Comparison
Compare BVN & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BVN | LEGN |
|---|---|---|
| Founded | 1953 | 2014 |
| Country | Peru | United States |
| Employees | N/A | N/A |
| Industry | Metal Mining | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.4B | 5.9B |
| IPO Year | 1996 | 2020 |
Fundamental Metrics
Financial Performance| Metric | BVN | LEGN |
|---|---|---|
| Price | $29.58 | $22.59 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 13 |
| Target Price | $27.00 | ★ $69.58 |
| AVG Volume (30 Days) | 1.7M | ★ 2.3M |
| Earning Date | 10-30-2025 | 11-12-2025 |
| Dividend Yield | ★ 0.99% | N/A |
| EPS Growth | ★ 20.28 | N/A |
| EPS | ★ 1.70 | N/A |
| Revenue | ★ $1,407,837,000.00 | $909,045,000.00 |
| Revenue This Year | $28.79 | $68.83 |
| Revenue Next Year | $14.32 | $51.27 |
| P/E Ratio | $17.22 | ★ N/A |
| Revenue Growth | 26.97 | ★ 74.75 |
| 52 Week Low | $11.50 | $21.19 |
| 52 Week High | $29.88 | $45.30 |
Technical Indicators
Market Signals| Indicator | BVN | LEGN |
|---|---|---|
| Relative Strength Index (RSI) | 75.04 | 33.52 |
| Support Level | $27.71 | $21.19 |
| Resistance Level | $29.88 | $23.24 |
| Average True Range (ATR) | 1.02 | 1.04 |
| MACD | 0.18 | 0.18 |
| Stochastic Oscillator | 91.08 | 21.26 |
Price Performance
Historical ComparisonAbout BVN Buenaventura Mining Company Inc.
Compania de Minas Buenaventura SAA is a Peruvian precious metals-producing company with experience in mine exploration, development, construction, and operation.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.